Epsilon M&A Deal Report - Aurelia Bioscience
Transaction Multiples for the Valuation of Private Companies
Charnwood Molecular / Aurelia Bioscience
No EMAT :
114304
Announced Date :
21/06/2021
Type :
Acquisition of Majority Stake
Deal Value :
Yes
Acquirer :
Charnwood Molecular
Target :
Aurelia Bioscience
Country :
England
Sector of activity :
- Health, Pharmaceuticals & Biotechnology > Biotechnology
Business Description :
Aurelia Bioscience Ltd is a contract research organisation (CRO). > Specialising in bioassay development, pharmacological profiling, compound screening. > Serves SMEs, universities, medical...
Transaction multiples available
| EV/ Sales |
EV/ Gross Profit |
EV/ EBITDA |
EV/ EBIT |
Eq/ PBT |
P/E | Price to Book |
Specific multiple(s) |
|
|---|---|---|---|---|---|---|---|---|
| Historic | 
|
|
||||||
| Current |
|
|
Rating :
**
|
|
Multiple available |
| n.s. | Multiple calculated, but not significant |
Source: Epsilon Research / EMAT
Comparable Transactions
- Number of EMAT Reports / sub-sector « Biotechnology » = 42
| Date | Acquirer | Target | Country | Multiples | See details |
| 31/03/2021 | Charles River Discovery Research Services UK | Retrogenix | England | ** | 114147 |
| 18/07/2023 | Groupe Vabel | Laboratoires Sarbec | Nord | * | 113988 |
Source: Epsilon Research / EMAT
